Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777943 | 0.84 | L3MBTL1 (0.60) | DUTL3MBTL1PKMKMT2AALDH1A1 | |
| SCHEMBL20333609 | 0.83 | PKM (0.51) | DUTL3MBTL1PKMEP300CRBN | |
| SCHEMBL17371792 | 0.83 | MAPT (0.51) | DUTL3MBTL1PKMKMT2ASMN1; SMN2 | |
| SCHEMBL19370625 | 0.83 | DUT (0.50) | DUTL3MBTL1PKMALDH1A1LMNA | |
| SCHEMBL20334334 | 0.83 | MAPT (0.58) | DUTL3MBTL1PKMKMT2AMEN1 | |
| SCHEMBL2800300 | 0.82 | DUT (0.59) | DUTALDH1A1CRBN | |
| SCHEMBL25370943 | 0.80 | ALDH1A1 (0.49) | DUTL3MBTL1PKMALDH1A1LMNA | |
| SCHEMBL7759057 | 0.80 | MAPT (0.57) | DUTL3MBTL1PKMKMT2AMEN1 | |
| SCHEMBL19370630 | 0.80 | DUT (0.48) | DUTL3MBTL1PKMALDH1A1LMNA | |
| SCHEMBL23498250 | 0.79 | EP300 (0.59) | DUTL3MBTL1PKMKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096907-A1 | Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents | INSTITUT PASTEUR (FR) | 2008-04-24 | — | — | US | disclosed |
| EP-1655288-A1 | Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents | INSTITUT PASTEUR (FR) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096907-A1 | Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents | TPMT, DHFR, TYMP | DUT 15/4885L3MBTL1 4099/4885PKM 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.